eligibility_summary
Eligibility: Patients with CD19+ R/R B-cell NHL, measurable disease, ECOG 0-1, adequate organ function, life expectancy >=12 weeks. Prior therapy: aggressive NHL >=2-3 lines incl CD20 + anthracycline/alkylator (if not for transplant, had/declined/ineligible for CAR T), FL >=2 lines with high-risk, incl CD20 + alkylator, MZL >=2 lines. Exclude: CNS-only disease (secondary CNS allowed), prior allo-SCT, significant CNS pathology, confounding comorbidities, or prohibited meds.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05336409 tests CNTY-101, an allogeneic induced‑pluripotent‑stem‑cell (iPSC)–derived CAR‑NK cell therapy, in relapsed/refractory CD19+ B‑cell non‑Hodgkin lymphomas. Mechanism: CAR-engineered NK cells recognize CD19 on malignant B cells and kill via NK cytotoxic pathways. Two dose schedules are explored (single dose vs three weekly doses), with or without supplemental interleukin‑2 (IL‑2). IL‑2 (cytokine) enhances NK activation, proliferation, and persistence via IL‑2 receptor signaling. Participants receive lymphodepleting chemotherapy beforehand to reduce host lymphocytes, improving CAR‑NK engraftment and activity. Targets/pathways: CD19 on B cells, NK cell activation/cytotoxic signaling, IL‑2/IL‑2R pathway, lymphocyte depletion of host T/B cells. Types: cellular immunotherapy (CAR‑NK), cytokine (IL‑2), and chemotherapy (lymphodepletion).